CHANDIGARH (A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 160011

Name	mn.	Ashani	Kum	ur			
UHID	: 132;	32541	Date :	281	6	12	4
Age	: ya	y1m	Gender :	^	1		_

# Nursing Assessment

	Profile
Height (cm): 170 cm	Waist Circumference (cm): 34 Inch
Weight (Kg.): 77 Kg	Body Mass Index: 26, 6kg/m2 18
Occupation :	Marital Status Single
spor - 994. 1	Vital Signs
Pulse Rate (/min): 78 bl mint	Respiratory Rate (/min) :
Blood Pressure (mmHg): 120/7am	
Pa	ast History
Hypertension :	Diabetes :
🕈 Heart disease :	Dyslipidemia :
Asthma :	Tuberculosis :
Allergies :	
Others :	
Others :	or Women
Others : Fo	br Women Last Pap smear done in
Others :	
Others : Fo LMP:	Last Pap smear done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others : Fo LMP: Menopause  Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others : Fo LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in

Signature, Name and Emp. ID of the Nurse :

Fortis MEDCENTRE Name My · Ashani Kumae UHID : 13232541 CHANDIGARH Date 28 06 24 (A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 160011 Age : 40 Gender :

Internal Medicine Consultation

**Relevant History:** - No complanti - No medication

Diagnosis: -obusity - wpw

77109 26.6141 m2

**Examination Findings:** 

Investigations: ECG-wpw . loge WTR .

Advice / Treatment Plan: - Dequeer Course. - Dequeer Course. - cardiology apinion - report.

Dr. MANJEET SINGHTREHAN MBBS,MD Additional Director-Internal Medicine (FMC) Reg. No.PMC 24797 Mobile No. + 91 9814104609 Fortis MECENTRE (A unit of Fortis Hospital, Mohali) S.C.C. 11 Sector 11-D Chandigarh-160011 (INDIA) Phone No.0172-5061222, 5055441, 6284163645

Fortis MEDCENTRE	Name		Mrs .	Ashani	Kym	nal	
CHANDIGARH (A unit of Fortis Hospital Mohali)	UHID	:_	132	32541	Date : 28	106	124
SCO 11, Sector 11-D, Chandigarh - 160011	Age	:_	40	1	_ Gender :	M	

**Ophthalmology** Consultation


LE

History: NIL


**Examination findings:** RG/Gisual acuity with glasses Visual acuity Slit Lamp Examination

Colour Vision

Clear



Fundus Examination




Diagnosis: NADBE

Treatment"

Spectacle prescription:

Right eye Left eye SPH CYL AXIS VA SPH AXIS CYL VA Distance Distance lla ON N 6 Near Near Signature and stamp of the Ophthalmologist :





#### Fortis Medcentre

 SCO-11, Sector-11-D,

 Chandigarh - 160 011 (India)

 Telephone : 0172 506 1222 / 505 5441

 Fax : 0172-5055440

 E-mail : contactus.fmc@fortishealthcare.com

 Website : www.fortishealthcare.com

## DEPARTMENT OF FMC-RADIOLOGY LAB

Date: 28/Jun/2024

Name: Mr. Ashani Kumar Age | Sex: 40 YEAR(S) | Male Order Station : FRONTOFFICE-FMC Bed Name : UHID | Episode No : 13232541 | 9604/24/10021 Order No | Order Date: 10021/PN/OP/2406/24652 | 28-Jun-2024 Admitted On | Reporting Date : 28-Jun-2024 11:34:10 Order Doctor Name : Dr.SELF .

#### CHEST X-RAY ( PA VIEW )

Both the domes of diaphragm are normal.

Both costophrenic angles are normal.

Both lung fields are clear.

Cardiac size and silhouette are normal.

Both hila and mediastinum are normal.

Bony cage and soft tissues are normal.

IMPRESSION: NORMAL STUDY.

Please correlate clinically and with other relevant investigations.


Dr. ADITI PANWAR

PMC - 41230

Consultant Radiologist

A unit of FORTIS HOSPITAL MOHALI

Sector 62, Phase - VIII, Mohali - 160062, Punjab (India); Tel: +91 172 469 2222, 469 2250 Fax: +91 172 469 2221





Fortis Medcentre

 SCO-11, Sector-11-D,

 Chandigarh - 160 011 (India)

 Telephone
 : 0172 506 1222 / 505 5441

 Fax
 : 0172-5055440

 E-mail
 : contactus.fmc@fortishealthcare.com

 Website
 : www.fortishealthcare.com

# NAME: MR. ASHANI KUMAR AGE AND SEX: 40Y/M UHID NO: 13232541 DATE: 28/06/2024 ROI: WHOLE ABDOMEN

Liver is normal in size, outline and echogenicity. No focal lesion seen. IHBR's are not dilated. Portal vein and hepatic veins are normal.

Gall bladder is normally distended with anechoic lumen. Wall thickness is normal. No calculus / focal lesion seen. No pericholecystic fluid / collection seen. CBD is normal.

Pancreas is visualized in region of and proximal body and is normal in size, shape, outline and echotexture. No focal lesion seen. Distal body and tail are obscured by bowel gases.

Spleen is normal in size, outline and echotexture. No focal lesion seen.

Right kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Left kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Retroperitoneum is normal.

The urinary bladder is fully distended and is normal in outline and wall thickness. No calculi or growth seen.

Prostate is normal in size and shows normal outline and echo pattern. No focal lesion seen.

No free fluid is seen.

**Opinion:** Normal study

Suggested clinical correlation.

Dr. ADIPI PANWAR PMC - 41230 Consultant Radiologist

> A unit of FORTIS HOSPITAL MOHALI Sector 62, Phase - VIII, Mohali - 160062, Punjab (India); Tel: +91 172 469 2222, 469 2250 Fax: +91 172 469 2221

KUMAR, ASHANI					Study Date: 28/06/2024
		Accession #			Alt ID:
Patient ID: 13232541 DOB: Institution: Fortis MEDC	Age: ENTRE, Chan	Gender: M	Ht:	Wt:	BSA:
Referring Physician: Physician of Record:				Performed	By:
Comments:					

# Images



# Signature

Signature: Name(Print):

Date:

Health checkup at tie-up Ctr	HealthChkup Authorisatn letter		
	यूनियन बैंक 🕥 Union Bank		
	Union Bank of India		
To,	RO - JALANDHAR P.B. NO. 144, VEER PARTAP BHAVAN, Shastri Market, Nehru Garden Road, Jalandhar, Punjab, Pin - 144 00		
The Chief Medical Officer			
M/S Mediwheel https://mediwheel.in/signup( 41195959(A brand name of Arcofemi Healthcare Ltd).	011-		
Mumbai400021			
Dear Sir,			
Tie-up arrangement for	Health Checkup under Health Checkup	40-50 Male	
Shri/Smt./Kum. ASHA	NI KUMAR,.		
P.F. No. 646126	Designation : Sr.CustomerService	ce Assoc(CASH)	
Checkup for Financial Y		3500.00	
. The above mentioned Hospital/Centre/Clinic, und	2025 staff member of our Branch/Office desires to underg fer the tie-up arrangement entered into with you, by o	o Health Checkup at your our bank.	
•			
. Please send the rece	pt of the above payment and the relevant reports to	our above address,	4
		र्यक्त अन्द्र	
Thanking you,	Yours Faithfully,		
Ashani Kuma		H 18728 5	
(Signature of the Employee	BRANCH MANAGER/SENIOR MA	NAGER	

PS.: Status of the application- Sanctioned

.

Health checkup at tie-up Ctr | HealthChkup Authorisatn letter

## EXERCISE STRESS TEST REPORT

DOB: 24.05.1984 Age: 40yrs Gender: Male Race: Indian

Referring Physician: --

Attending Physician: DR MANJEET/DR VIJAY HARJAI

Patient Name:	KUMAR,	ASHAN
Patient ID: 13	232541	
Height: 170 cr	n	
Weight: 77 kg		

Study Date: 28.06.2024 Test Type: --Protocol: BRUCE

M	e	di	ca	ti	or	15

Medical History:

---

Reason for Exercise Test:

### Exercise Test Summary

Phase Name	Stage Name	Time in Stage	Speed (km/h)	Grade (%)	HR (bpm)	BP (mmHg)	Comment
PRETEST	SUPINE '	00:03	0.00	0.00	90		
	STANDING	00:05	0.00	0.00	90		1
	HYPERV.	00:39	0.00	0.00	90	120/70	
	WARM-UP	01:01	1.60	0.00	101		
EXERCISE	STAGE 1	03:00	2.70	10.00	110	120/70	
	STAGE 2	03:00	4.00	12.00	123	140/70	
	STAGE 3	03:00	5.50	14.00	139	140/70	
	STAGE 4	01:13	6.80	16.00	153	140/70	
RECOVERY		03:03	0.00	5.80		130/80	

The patient exercised according to the BRUCE for 10:12 min:s, achieving a work level of Max. METS: 13.70. The resting heart rate of 91 bpm rose to a maximal heart rate of 153 bpm. This value represents 85% of the maximal, age-predicted heart rate. The resting blood pressure of 120/70 mmHg, rose to a maximum blood pressure of 140/80 mmHg. The exercise test was stopped due to Target heart rate achieved.


## Interpretation


Summary: Resting ECG: normal. Functional Capacity: normal. HR Response to Exercise: appropriate. BP Response to Exercise: normal resting BP - appropriate response. Chest Pain: none. Arrhythmias: none.

# Conclusions negative for modernite solverme

Dr. MANJEET SINGHTREHAN	
MBBS,MD	-
moba, mu VV V	
Additional Director-Internal Medicine (FMC)	
Reg. No.PMC-24797	
Mobile No. + 91 9814104609	
	)
	1
Phone No.0172-5061222, 5055441, 6284163645	
Mobile No. + 91 9814104609 Fertis MECENTRE (A unit of Fortis Hospital, Mohali 5,C.Q. 11, Sector 11-D, Chandigarh-160011 (INDIA) Phone No.0172-5061222, 5055441, 6284163645	)

(%) CARDIDPRINT





GE CardioSi 25 mm/s 10								KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:45:41pm
mm/mV 50Hz 0	avr-yht 0.70 0.81	aVL-44	aVR/11/	III ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	II ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		BASELINE 60 ms post J	ASHANI [323254]
GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 40Hz S+ HR(V3,V5) (+3 CARDIOPRINT)	aVE-1/14	aVL	aVRV///	III ~ ///~ 0.65 0.69	11 - ALAS	-0.20 -0.08	CURRENT 60 ms post J	
<b></b> ((¥3,\¥5)	Andrew	Jam Man Ja	frank my	Aman	Andread	Iml		114 bpm 120/70 mmHg
	why		m	mpp	whent	·		Comparative Medians Report EXERCISE STAGE 1 02:50
Sta	V6-14-	V5	0.40 0.33	v3-√/+~	v2-JH- -0.05 -0.24	V1-4/H~ -0.20 -0.68		
Start of Test: 12:41:07pm	V6 - 14-	V5 - WH	V4 - WH	0.00 0.19	v2)	V1		BRUCE 2.7 km/h 10.0 %
7pm	bout	Jan				- martine	ST:S	Lead
	AL	A A	when			- Int	ST Level (mm) ST Slope (mV/s)	Fortis MEC

mq	Start of Test: 12:41:07pm	R(V3,V5)	GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 40Hz S+ HR(V3,V5)
of the standard	V6 1 V6 1 4	anternation and the second	ave when ave when ave when ave when ave when ave
to have been been been been been been been be	Vs - WH - Vs - WH - 0.45 0.05 0.50 0.07	adam a parter proved for	aVL+H- aVL+H- -0.30 -0.45 -0.59 -0.48
zylandundensk	0.40 0.33 0.15	Multimution	avr./// avr.///
- ilmulant	V3 - + + + - V3 - + + + 0.15 0.16 - 0.14	Mon Andrew Manual Mar	III - 14 IIII - 14 IIII - 14 IIIII - 14 IIII - 14 IIIIII - 14 IIIII - 14 IIIIIIIIII
- June June	$v_2 - \frac{1}{1} + v_2 - \frac{1}{1} + \frac{1}{0.11}$	mm hay way hay h	11 M/ 11 M/ 0.70 0.45 0.82 0.14
Ay manufamentant	-0.20 -0.68 -0.78	Tolum have been been and have a	0.10 0.03 0.03 -0.48
ST Level (mm) ST Slope (mV/s)			BASELINE CURRENT 60 ms post J 60 ms post J
Fortis ME	Report BRUCE 4.0 km/h 12.0 %	Comparative Medians Report EXERCISE STAGE 2 05:50	KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:48:41pm

'pm	Start of Test: 12:41:07pm	(V2,V3)	GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 20Hz S+ HR(V2,V3)
antrylander	V6 - V6 - V6 - V6 0.45 -0.15 0.63 0.23	summer and the second	ave when ave when ave when ave
salud Alut	vs when vs when vs when vs of the vs	adammant	aVI-H+- aVI-H+-
and	V4 - When V4 - When V4 - 0.40 -0.40 -0.38 -0.38	Juliul Marie	aVR A
	V3-44- V3-44-	Harman	III - W/ III - W/ - 0.70 0.40 0.87 0.90
and when the	$v_2 - H - v_2 - H 0.05 - 0.24 - 0.89 - 0.89$	and when have have	11 - W II W
approximation	VI	- Martine	0.10 0.03 0.03 0.45
ST Level (mm) ST Slope (mV/s)			BASELINE CURRENT 60 ms post J 60 ms post J
Fortis ME	Report BRUCE 5.3 km/h 14.0 %	Comparative Medians Report EXERCISE 137 bpm 140/70 mmHg 08:50	KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:51:41pm

7pm	Start of Test: 12:41:07pm	R(V2,V3)	GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 20Hz S+ HR(V2,V3)
of the second	V6	man when we we	ave 14 ave 14
mprophy the	0.45 -0.80 0.50 0.28	and when have the	aVIE-AL- aVIE-AL- -0.30 -0.60 -0.59 0.46
valad man	0.40 0.33 0.22	and the second	aventift aventift
and the	V3 - + + + - V3 - + + 1.10 0.16 0.23	M. M. M.	III ALA III ALA
A man man	$v_2 - v_2 $	In Marken and Marken	II W II W
mp when he when he	-0.20 -0.68 -0.12	- Many	
ST Level (mm) ST Slope (mV/s)			BASELINE CURRENT 60 ms post J 60 ms post J
Fortis ME	Comparative Medians Report (PEAK EXERCISE ) EXERCISE BRUCE STAGE 4 6.8 km/h 10:13 16.0 %	Comparative Medians EXERCISE STAGE 4 10:13	KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:53:04pm

			(⇒)[GARDIGPRINT] <sup>®</sup> C€
7pm	Start of Test: 12:41:07pm	R(V2,V3)	GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 20Hz S+ HR(V2,V3)
for the stand	V6 1 V6 1 V6	Wenter Mayne	aVF MA aVF MA 0.70 -0.10 0.81 1.28
Januar Martin	V5 WHAT V5 WHAT 0.45 -0.40 0.35 -0.35	after my when	ave-1/1- ave-1/1- -0.30 -0.15 -0.59 -0.41
	V4 - WH - V4 - WH - 0.45 0.33 0.24	Jury Munder	aVR./// aVR.//// -0.40 0.25 -0.98 -1.54
	V3 - + + - V3 - + + 0.50 0.16 - 0.60 0.02	theman	III ~
	$v_2 - J_{H} - v_2 - J_{H} 0.05 - 0.24 - 0.27 - 0.27$	the and	II - MAA II - MAA 0.70 -0.25 0.82 1.53
month of the	VI - VI - VI - VI - VI - 0.20 -0.68 -0.91	- Andrikan	
ST Level (mm) ST Slope (mV/s)			BASELINE CURRENT 60 ms post J 60 ms post J
Fortis MEC	Report BRUCE 2.4 km/h 5.8 %	Comparative Medians Report RECOVERY #1 00:50	KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:53:53pm

7pm	Start of Test: 12:41:07pm	(EV	GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV S0Hz 0.01 - 20Hz S+ HR(V2,V3)
forthered	V6 - 1 V6	adamanta	ave when ave when ave
testing	0.45 0.50 -0.05 0.41	mandad	ave-1/4- ave-1/4- AVE-
	$v_4$	« Inthe the	-0.40 aVR./// aVR./// aVR./// aVR./// aVR.///
	$v_3 - v_1 + v_3 - v_3 + v_3 - v_3 + v_3 - v_3 + v_3 + v_3 - v_3 + v_3 $	Maryand	III - VAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
	$v_2 - H - v_2 - H - 0.05 - 0.24 0.35 - 0.67$	munutur	II - W II - W II - W II - U
	-0.20 0.35 -0.68 -0.21		
ST Level (mm) ST Slope (mV/s)			60 ms post J 60 ms post J
Fortis ME	Report BRUCE 0.0 km/h 5.8 %	Comparative Medians Report RECOVERY 117 bpm #1 130/80 mmHg 01:50	KUMAR, ASHANI Patient ID 13232541 28.06.2024 12:54:53pm 130

GE CardioSoft V6.73 (2) 25 mm/s 10 mm/mV 50Hz 0.01 - 20Hz S+ HR(V5,V2)	ave 1	AVE-0.30	4VR~1	HII	HI	0.10 0.03	28.06.2024 12:55:53pm BASELINE 0 ms post J
Iz S+ HR(V5,V2)	avr	aVL	aVR				130/80 mmHg
							#1 02:50
· Start of T	- 146 - 145 0.45 0.63	0.45 0.50	0.40 0.33	0.30 0.16		- k1 / 0.20 - 0.68	0.0 km/h 5.9 %
Start of Test: 12:41:07pm	46	VS	* 4	<b>V</b> 3	¥2	· V	
							Lead ST Level (mm) ST Slope (mV/s)





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI, MOHALI 160062 7087030817	ACCESSION NO : <b>0006XF026995</b> PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541 ABHA NO :	AGE/SEX :40 Years Male DRAWN :28/06/2024 10:32:00 RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22
CLINICAL INFORMATION :		•

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status P	<u>reliminary</u>	Results	Biological Reference	Interval Units
	H	AEMATOLOGY - CBC		
CBC-5, EDTA WHOLE BL	00D			
BLOOD COUNTS, EDTA	VHOLE BLOOD			
HEMOGLOBIN (HB) METHOD : SLS- HEMOGLOBIN DE	TECTION METHOD	14.6	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC METHOD : HYDRODYNAMIC FOCU		4.49 Low	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (W METHOD : FLOWCYTOMETRY	BC) COUNT	5.92	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD : HYDRO DYNAMIC FOCH	JSING METHOD / MICROSCOPY	173	150 - 410	thou/μL
RBC AND PLATELET IND	ICES			
HEMATOCRIT (PCV) METHOD : HYDRODYNAMIC FOCU	SING	44.9	40.0 - 50.0	%
MEAN CORPUSCULAR V METHOD : CALCULATED PARAMET	· · ·	100.0	83.0 - 101.0	fL
MEAN CORPUSCULAR H METHOD : CALCULATED PARAMET	. ,	32.5 High	27.0 - 32.0	pg
MEAN CORPUSCULAR H CONCENTRATION(MCHC METHOD : CALCULATED PARAMET	EMOGLOBIN	32.5	31.5 - 34.5	g/dL
RED CELL DISTRIBUTIO METHOD : CALCULATED PARAMET	N WIDTH (RDW)	14.0	11.6 - 14.0	%
MENTZER INDEX METHOD : CALCULATED PARAMET		22.3		
MEAN PLATELET VOLUM METHOD : CALCULATED PARAMET	IE (MPV)	13.4 High	6.8 - 10.9	fL

Ritu Pankay

Shafia

Meenahshi Malhotra

Page 1 Of 16

1

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897 Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159





View Report

View Details

ULR No.6000003424507-0006

PERFORMED AT : CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	REI	F. DOCTOR :	SELF	
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI, MOHALI 160062 7087030817	ACCESSION NO : <b>0006XFC</b> PATIENT ID : FH.13232 CLIENT PATIENT ID: UID:13232 ABHA NO :	2541	DRAWN RECEIVED	:40 Years Male :28/06/2024 10:32:00 :28/06/2024 14:12:09 :28/06/2024 16:04:22
CLINICAL INFORMATION :			<u>i</u>	
UID:13232541 REQNO-1720515 CORP-OPD BILLNO-1002124OPCS011998 BILLNO-1002124OPCS011998				
Test Report Status <u>Preliminary</u>	Results	Biological	Reference	e Interval Units
WBC DIFFERENTIAL COUNT NEUTROPHILS METHOD : FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOPY	47	40.0 - 80.	.0	%
LYMPHOCYTES	44 High	20.0 - 40.	.0	%
METHOD : FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOPY MONOCYTES METHOD : FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOPY	6	2.0 - 10.0	)	%
EOSINOPHILS METHOD : FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOPY	3	1 - 6		%
BASOPHILS METHOD : FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOPY	00	0 - 2		%
ABSOLUTE NEUTROPHIL COUNT METHOD : CALCULATED PARAMETER	2.78	2.0 - 7.0		thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	2.60	1.0 - 3.0		thou/µL

METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT 0.18 0.02 - 0.50 thou/µL METHOD : CALCULATED PARAMETER NEUTROPHIL LYMPHOCYTE RATIO (NLR) 1.1METHOD : CALCULATED PARAMETER

0.36

Interpretation(s) RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Ritu Pankay

Shafua

Meenahahi Malhotra

Page 2 Of 16

Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897

ABSOLUTE MONOCYTE COUNT

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

0.2 - 1.0





View Report

Vie<u>w Details</u>



thou/µL

**PERFORMED AT :** CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASH	IANI KUMAR		<b>REF. DOCTOR :</b>	SELF		
FORTIS MOHALI-CHC -S FORTIS HOSPITAL - MC MOHALI 160062 7087030817	DHALI,	PATIENT ID	) : <b>0006XF026995</b> : FH.13232541 ID: UID:13232541 :	i	:40 Years :28/06/2024 :28/06/2024 :28/06/2024	14:12:09
CLINICAL INFORMATIO	N :					
UID:13232541 REQNO- CORP-OPD BILLNO-10021240PCSC BILLNO-10021240PCSC	11998					
Test Report Status	<u>Preliminary</u>	Results	Biological	Referenc	e Interval	Units
		HAEMATOLO	GY			
	IENTATION RATE (ESR),					
E.S.R METHOD : WESTERGREN MET	нор	04	0 - 14		mr	n at 1 hr
GLYCOSYLATED HEM	DGLOBIN(HBA1C), EDTA	WHOLE BLOOD	2			
HBA1C		5.3	Pre-diabe	etic: < 5.7 tics: 5.7 - : > or = 6	6.4	

		Therapeutic goals: < Action suggested : > (ADA Guideline 2021	> 8.0
METHOD : HPLC ESTIMATED AVERAGE GLUCOSE(EAG)	105.4	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER			

#### Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a same of blood that has been placed into a tail, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging. Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

#### LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine,

Ritu Pankay



Meenahah Malhotra

Page 3 Of 16

Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





View Details



**PERFORMED AT :** CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b> S	SELF
FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL – MOHALI, MOHALI 160062	PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541	AGE/SEX :40 Years Male DRAWN :28/06/2024 10:32:00 RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22
CLINICAL INFORMATION :		

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

#### **Test Report Status** Results **Biological Reference Interval** Units **Preliminary**

salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

Evaluating the long-term control of blood glucose concentrations in diabetic patients.
 Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

AG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

HbA1c Estimation can get affected due to :

Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

2.Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

Tron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.
 Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.) c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Ritu Pantay

Shafia Dr. Shafira Garg (MD, Pathology)

Attending Consultant, 47150

Meenahsh Malhotra

Page 4 Of 16

Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





View Details



**PERFORMED AT :** CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), Fax: 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com







PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS	ACCESSION NO : 0006XF026995	AGE/SEX : 40 Years Male
FORTIS MOHALI-CHC -SPLZD	PATIENT ID : FH.13232541	DRAWN :28/06/2024 10:32:00
FORTIS HOSPITAL – MOHALI, MOHALI 160062	CLIENT PATIENT ID: UID:13232541	RECEIVED : 28/06/2024 14:12:09
7087030817	ABHA NO :	REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status <u>Preliminary</u>	Results	Biological Reference	Interval Units
	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD : DIAZONIUM ION, BLANKED (ROCHE)	1.93 High	UPTO 1.2	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZOTIZATION	0.37 High	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	1.56 High	0.00 - 0.60	mg/dL
TOTAL PROTEIN METHOD : BIURET	7.8	6.6 - 8.7	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.8	3.97 - 4.94	g/dL
GLOBULIN	3.0	2.0 - 4.0 Neonates - Pre Mature: 0.29 - 1.04	g/dL
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.6	1.0 - 2.0	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	24	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : UV WITHOUT PYRIDOXAL-5 PHOSPHATE	28	0 - 41	U/L
ALKALINE PHOSPHATASE METHOD : PNPP - AMP BUFFER	90	40 - 129	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	32	8 - 61	U/L
LACTATE DEHYDROGENASE	191	135 - 225	U/L

METHOD : LACTATE - PYRUVATE UV

#### **GLUCOSE FASTING, FLUORIDE PLASMA**

Ritu Pankoy

Meenahah Malhotra

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897 Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159

Ms. Hardeep Kaur, M.Sc. Biochemistry



View Report

Page 5 Of 16

View Details



**PERFORMED AT :** 

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS	ACCESSION NO : 0006XF026995	AGE/SEX : 40 Years Male
FORTIS MOHALI-CHC -SPLZD	PATIENT ID : FH.13232541	DRAWN :28/06/2024 10:32:00
FORTIS HOSPITAL – MOHALI, MOHALI 160062 7087030817	CLIENT PATIENT ID: UID:13232541	RECEIVED : 28/06/2024 14:12:09
	ABHA NO :	REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interva	l Units
FBS (FASTING BLOC	D SUGAR)	80	(Normal <100,Impaired fas glucose:100 to 125,Diabete mellitus:>=126(on more th 1 occasion)(ADA guidelines 2024)	S
BLOOD UREA NITRO BLOOD UREA NITRO METHOD : UREASE - UV	• •	8	6 - 20	mg/dL
URIC ACID, SERUM URIC ACID METHOD : URICASE, COLOR	IMETRIC	7.0	3.4 - 7.0	mg/dL
CREATININE EGFR CREATININE METHOD : ALKALINE PICRAT AGE	E-KINETIC	0.90 40	0.70 - 1.20	mg/dL years

Ritu Pankoy

Meenahshi Malhotra

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. Biochemistry

Ø. 

200





Page 6 Of 16

1



**PERFORMED AT :** CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS	ACCESSION NO : 0006XF026995	AGE/SEX : 40 Years Male
FORTIS MOHALI-CHC -SPLZD	PATIENT ID : FH.13232541	DRAWN :28/06/2024 10:32:00
FORTIS HOSPITAL – MOHALI, MOHALI 160062	CLIENT PATIENT ID: UID:13232541	RECEIVED : 28/06/2024 14:12:09
7087030817	ABHA NO :	REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interv	al Units
GLOMERULAR FILTR	ATION RATE (MALE)	111	GFR of +90 normal or minimal kidney damage with normal GFR 89- 60 mild decrease 59-30 moderate decrease 29-15 severe decrease < 15 kidney failure	mL/min/1.73mSq
Interpretation(s)				
GLUCOSE POST-PRA	NDIAL, PLASMA			
PPBS(POST PRANDIA	AL BLOOD SUGAR)	91	Non-Diabetes 70 - 140	mg/dL

METHOD : HEXOKINASE

#### Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis.obstruction of bile ducts.cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen

Ritu Pantaj

Meenahah Malhotra

Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 





Page 7 Of 16

Vie<u>w Details</u>



**PERFORMED AT :** CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME: ASHANI KUMAR	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI, MOHALI 160062 7087030817	ACCESSION NO : <b>0006XF026995</b> PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541 ABHA NO :	AGE/SEX       :40 Years       Male         DRAWN       :28/06/2024       10:32:00         RECEIVED       :28/06/2024       14:12:09         REPORTED       :28/06/2024       16:04:22
CLINICAL INFORMATION : UID:13232541 REQNO-1720515 CORP-OPD	i	<u>.</u>

BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

l	Test Report Status	<u>Preliminary</u>	Results	<b>Biological Reference Interval</b>	Units

in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION** 

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolo);sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. BLOOD UREA NITROGEN (BUN), SERUM-**Causes of Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Causes of decreased level include Liver disease, SIADH. URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic

syndrome **Causes of decreased levels**-Low Zinc intake, OCP, Multiple Sclerosis GLUCOSE POST-PRANDIAL, PLASMA-Spectrophotometry Hexokinase



Meenahsh Malhotra

Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159

Ms. Hardeep Kaur, M.Sc. **Biochemistry** 





View Report

Page 8 Of 16

View Details



#### **PERFORMED AT :**

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI, MOHALI 160062 7087030817	ACCESSION NO : <b>0006XF026995</b> PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541 ABHA NO :	AGE/SEX :40 Years Male DRAWN :28/06/2024 10:32:00 RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status <u>Preliminary</u>	Results	Biological Reference Interval	l Units
	BIOCHEMISTRY - LIPI	D	
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	188	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDA	SE		
TRIGLYCERIDES	128	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/= 500 Very High	mg/dL
METHOD : ENZYMATIC ASSAY			
HDL CHOLESTEROL	40	< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASURE - PEG			
LDL CHOLESTEROL, DIRECT	129 High	< 100 Optimal 100 - 129 Near or above optimal 130 - 160 Borderline High 161 - 189 High >/= 190 Very High	mg/dL
METHOD : CHOLESTEROL OXIDASE, ESTERASE, PEROXIDA	SE		
NON HDL CHOLESTEROL	148 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
VERY LOW DENSITY LIPOPROTEIN	25.6	Desirable value : 10 - 35	mg/dL
METHOD : CALCULATED PARAMETER			
CHOL/HDL RATIO	4.7 High	3.3-4.4 Low Risk 4.5-7.0 Average Risk 7.1-11.0 Moderate Risk > 11.0 High Risk	

Ritu Pankoy

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. Biochemistry

Meenahshi Malhotra

Page 9 Of 16

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159







ULR No.6000003424507-0006 

**PERFORMED AT :** 

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS	ACCESSION NO : 0006XF026995	AGE/SEX : 40 Years Male
FORTIS MOHALI-CHC -SPLZD	PATIENT ID : FH.13232541	DRAWN :28/06/2024 10:32:00
FORTIS HOSPITAL – MOHALI,	CLIENT PATIENT ID: UID:13232541	RECEIVED : 28/06/2024 14:12:09
MOHALI 160062 7087030817	ABHA NO :	REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval Units	J
LDL/HDL RATIO		3.2 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
METHOD : CALCULATED PAR	AMETER			

Interpretation(s)

Ritu Pankay

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897

Ms. Hardeep Kaur, M.Sc. Biochemistry

Meenahshi Malhotra

Page 10 Of 16

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant, 48159





View Details



**PERFORMED AT :** 

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	R REF. DOCTOR : SELF		
CODE/NAME & ADDRESS : C000045483 - FORT FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL – MOHALI, MOHALI 160062 7087030817	IS ACCESSION NO : <b>0006X</b> PATIENT ID : FH.132 CLIENT PATIENT ID: UID:13 ABHA NO :	232541 DRAWN :28/06/2024 10:32:00	)
CLINICAL INFORMATION : UID:13232541 REQNO-1720515 CORP-OPD BILLNO-1002124OPCS011998 BILLNO-1002124OPCS011998	I		
Test Report Status <u>Preliminary</u>	Results	Biological Reference Interval Units	
С	LINICAL PATH - URINALYSI	19	
URINALYSIS PHYSICAL EXAMINATION, URINE			ر
COLOR METHOD : MANUAL EXAMINATION APPEARANCE METHOD : MANUAL EXAMINATION	LT. YELLOW CLEAR		
CHEMICAL EXAMINATION, URINE			
	6.0	4.7 - 7.5	
METHOD : DOUBLE INDICATOR PRINCIPLE SPECIFIC GRAVITY METHOD : REFLECTANCE PHOTOMETRY (IONIC CONCENTRA'	1.020 пом)	1.003 - 1.035	
PROTEIN METHOD : REFLECTION PHOTOMETRY (PROTEIN ERROR IND	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE PHOTOMETRY ( GLUCOSE OXIDASE KETONES METHOD : REFLECTION PHOTOMETRY (NITROPRUSSIDE)	NOT DETECTED	NOT DETECTED	
BLOOD METHOD : REFLECTANCE PHOTOMETRY ( BENZIDINE REACT		NOT DETECTED	
BILIRUBIN METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO RE/	NOT DETECTED	NOT DETECTED	
UROBILINOGEN METHOD : REFLECTANCE PHOTOMETRY (EHRLICH'S REACTION	NORMAL	NORMAL	
NITRITE METHOD : REFLECTANCE SPECTROPHOTOMETRY (DIAZO RE/	NOT DETECTED	NOT DETECTED	

#### **MICROSCOPIC EXAMINATION, URINE**

Imeet

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080 Meenahsh Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159 Ritu Pantaj

Page 11 Of 16

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897





View Details



PERFORMED AT : CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
	ACCESSION NO : 0006XF026995	AGE/SEX : 40 Years Male
FORTIS MOHALI-CHC -SPLZD	PATIENT ID : FH.13232541	DRAWN :28/06/2024 10:32:00
FORTIS HOSPITAL – MOHALI, MOHALI 160062	CLIENT PATIENT ID: UID:13232541	RECEIVED : 28/06/2024 14:12:09
	ABHA NO :	REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<b>Preliminary</b>	Results	Biological Reference I	Interval Units
RED BLOOD CELLS		NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)		NOT DETECTED	0-5	/HPF
EPITHELIAL CELLS		NOT DETECTED	0-5	/HPF
CASTS		NOT DETECTED		
CRYSTALS		NOT DETECTED		
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : REFLECTANCE SPE	ECTROPHOTOMETRY	NOT DETECTED	NOT DETECTED	

Interpretation(s)

Ineet

Dr. Irneet Mundi (MD,DNB Pathology) Associate Consultant, 34080 Meenahsh Malhotra

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159 Ritu Pankay

Page 12 Of 16

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897





View Details



PERFORMED AT : CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





\_

PATIENT NAME: ASHANI KUMAR	<b>REF. DOCTOR :</b> S	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI, MOHALI 160062 7087030817	PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541	AGE/SEX :40 Years Male DRAWN :28/06/2024 10:32:00 RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22

#### CLINICAL INFORMATION :

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<u>Preliminary</u>	Results	Biological Reference Interval	Units
	CL	INICAL PATH - STOOL ANALY	/SIS	
STOOL: OVA & PARA	SITE	RESULT PENDING		
PHYSICAL EXAMINA	TION,STOOL	<b>RESULT PENDING</b>		
CHEMICAL EXAMINA	TION, STOOL	<b>RESULT PENDING</b>		
MICROSCOPIC EXAM	IINATION,STOOL	<b>RESULT PENDING</b>		

Page 13 Of 16



View Report

View Details







PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000045483 - FORTIS FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL - MOHALI,		AGE/SEX : 40 Years Male DRAWN : 28/06/2024 10:32:00
MOHALI 160062 7087030817		RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status	<u>Preliminary</u>	Results	Biological Reference I	nterval Units
		ALISED CHEMISTRY - H	ORMONE	
THYROID PANEL, SE	<u>RUM</u>			
T3		154.6	80.00 - 200.00	ng/dL
T4		9.51	5.10 - 14.10	µg/dL
TSH (ULTRASENSITI	VE)	1.080	0.270 - 4.200	µIU/mL

Meenahshi Malhotra

Ritu Pankay

Dr. Meenakshi Malhotra (MD, Pathology) Senior Consultant,48159



View Details



Page 14 Of 16

new Details



Ø,

**PERFORMED AT :** CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





PATIENT NAME : ASHANI KUMAR	<b>REF. DOCTOR :</b> S	SELF
FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL – MOHALI, MOHALI 160062	PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541	AGE/SEX:40 YearsMaleDRAWN:28/06/202410:32:00RECEIVED:28/06/202414:12:09REPORTED:28/06/202416:04:22
CLINICAL INFORMATION : UID:13232541 REONO-1720515		

CORP-OPD BILLNO-10021240PCS011998 BILLNO-1002124OPCS011998

Test Report Status	<b>Preliminary</b>	Results	<b>Biological Reference Interva</b>	l Units
SPECIALISED CHEMISTRY - TUMOR MARKER				
PROSTATE SPECIFIC	ANTIGEN, SERUM			
PROSTATE SPECIFIC	ANTIGEN	0.796	0.0 - 2.0	ng/mL

Interpretation(s)
PROSTATE SPECIFIC ANTIGEN, SERUM-- PSA is detected in the male patients with normal, benign hyperplastic and malignant prostate tissue and in patients with prostatitis. - PSA is not detected (or detected at very low levels) in the patients without prostate tissue (because of radical prostatectomy or cystoprostatectomy) and also in the female patients.

It a suitable marker for monitoring of patients with Prostate Cancer and it is better to be used in conjunction with other diagnostic procedures.

Serial PSA levels can help determine the success of prostatectomy and the need for further treatment, such as radiation, endocrine or chemotherapy and useful in detecting residual disease and early recurrence of tumor.

Elevated levels of PSA can be also observed in the patients with non-malignant diseases like Prostatitis and Benign Prostatic Hyperplasia.
 Specimens for total PSA assay should be obtained before biopsy, prostatectomy or prostatic massage, since manipulation of the prostate gland may lead to elevated PSA

(false positive) levels persisting up to 3 weeks. - As per American urological guidelines, PSA screening is recommended for early detection of Prostate cancer above the age of 40 years. Following Age specific reference

between 4-10 ng/mL.

- Total PSA values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. Recommended follow up on same platform as patient result can vary due to differences in assay method and reagent specificity.

#### References-

1. Burtis CA, Ashwood ER, Bruns DE. Teitz textbook of clinical chemistry and Molecular Diagnostics. 4th edition.

2. Williamson MA, Snyder LM. Wallach's interpretation of diagnostic tests. 9th edition.

#### \*\*End Of Report\*\*

Please visit www.agilusdiagnostics.com for related Test Information for this accession



Dr. Ritu Pankaj (MD, Pathology), PDCC Additional Director, 30897



Page 15 Of 16

View Details







PATIENT NAME: ASHANI KUMAR	<b>REF. DOCTOR :</b> S	SELF
FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL – MOHALI, MOHALI 160062	PATIENT ID : FH.13232541 CLIENT PATIENT ID: UID:13232541	AGE/SEX :40 Years Male DRAWN :28/06/2024 10:32:00 RECEIVED :28/06/2024 14:12:09 REPORTED :28/06/2024 16:04:22
CLINICAL INFORMATION :	l	<u> </u>

UID:13232541 REQNO-1720515 CORP-OPD BILLNO-10021240PCS011998 BILLNO-10021240PCS011998

Test Report Status Preliminary

Results

**Biological Reference Interval** Units

CONDITIONS OF LABORAT	ORY TESTING & REPORTING
<ol> <li>It is presumed that the test sample belongs to the patient named or identified in the test requisition form.</li> <li>All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.</li> <li>Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.</li> <li>A requested test might not be performed if:         <ol> <li>Specimen received is insufficient or inappropriate ii. Specimen quality is unsatisfactory iii. Incorrect specimen type iv. Discrepancy between identification on specimen container label and test requisition form</li> </ol> </li> </ol>	<ol> <li>AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety &amp; technical integrity.</li> <li>Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.</li> <li>Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.</li> <li>Test results cannot be used for Medico legal purposes.</li> <li>In case of queries please call customer care (91115 91115) within 48 hours of the report.</li> </ol>
	A silver Discuss other Lineits d

**Agilus Diagnostics Limited** 

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Ritu Pankaj

Dr. Ritu Pankaj (MD,Pathology), PDCC Additional Director, 30897

CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62,Phase Viii, Mohali, 160062 Punjab, India Tel : 0172-469-2222 Extn. 6726, 6727), Fax : 0172-469-2221 - CIN -L85110DL1996PLC076704 Email : lab.mohali@fortishealthcare.com





Page 16 Of 16

View Details

